Cardiovascular and all‐cause mortality in patients with intermittent claudication and critical limb ischaemia. BJS 2018; 105: 252-261.
Published: 8th November 2017
Authors: S. T. W. van Haelst, C. Koopman, H. M. den Ruijter, F. L. Moll, F. L. Visseren, I. Vaartjes et al.
The aim of this study was to evaluate absolute mortality risks and to determine whether changes in mortality risk occurred in patients with intermittent claudication (IC) or critical limb ischaemia (CLI) in the Netherlands between 1998 and 2010.
Data for patients treated between 1998 and 2010 were obtained from Dutch nationwide registers: the Hospital Discharge Register, Population Register and Cause of Death Register. The registers were used to obtain information regarding IC and CLI hospitalizations, co‐morbidities, demographic factors, and date and cause of death. The cohort was split into two time intervals for comparison: 1998–2004 (period 1) and 2005–2010 (period 2). Thirty‐day mortality was excluded to eliminate per‐admission complications. One‐ and 5‐year cardiovascular and all‐cause mortality rates were compared with those of a representative sample of the general Dutch population (28 494 persons) by Cox proportional hazards models.
Some 47 548 patients were included, 34 078 with IC and 13 470 with CLI. In patients with IC, the age‐adjusted 5‐year mortality risk for cardiovascular disease decreased significantly in period 2 (14·1 per cent) compared with that in period 1 (16·1 per cent) in men only (5‐year adjusted hazard ratio (HR) 0·76, 95 per cent c.i. 0·69 to 0·83;
The risk of premature death in patients with IC and CLI declined significantly in the Netherlands, in a sex‐specific manner, over the period from 1998 to 2010. The absolute risk of cardiovascular mortality remains high in these patients.Full text
You may also be interested in
Authors: H. Shiwani, P. Baxter, E. Taylor, M. A. Bailey, D. J. A. Scott
Authors: R. Mouton, C. A. Rogers, R. A. Harris, R. J. Hinchliffe
Notes: Improves 30‐day survival
Long‐term outcomes of endovenous laser ablation and conventional surgery for great saphenous varicose veins.
Authors: T. Wallace, J. El‐Sheikha, S. Nandhra, C. Leung, A. Mohamed, A. Harwood et al.
Notes: EVLA lower recurrence at 5 years
Authors: A. J. A. Meershoek, G. J. de Borst
Predicting risk of rupture and rupture‐preventing reinterventions following endovascular abdominal aortic aneurysm repair. BJS 2018; 105: 1294-1304.
Authors: I. Grootes, J. K. Barrett, P. Ulug, F. Rohlffs, S. J. Laukontaus, R. Tulamo et al.
Notes: Potential to tailor surveillance
Authors: O. Grip, A. Wanhainen, K. Michaëlsson, L. Lindhagen, M. Björck
Notes: Endo may save lives
Authors: B. M. Biccard, A. Sigamani, M. T. V. Chan, D. I. Sessler, A. Kurz, J. G. Tittley et al.
Notes: No evidence to start or stop aspirin
Authors: P. A. Coughlin, J. H. F. Rudd
Population‐based study of mortality and major amputation following lower limb revascularization. BJS 2018; 105: 1145-1154.
Authors: K. Heikkila, I. M. Loftus, D. C. Mitchell, A. S. Johal, S. Waton, D. A. Cromwell et al.
Notes: lower than previously estimated
Cost‐effectiveness of population‐based vascular disease screening and intervention in men from the Viborg Vascular (VIVA) trial. BJS 2018; 105: 1283-1293.
Authors: R. Søgaard, J. S. Lindholt
Notes: Highly cost‐effective
Five‐year follow‐up of a randomized clinical trial comparing open surgery, foam sclerotherapy and endovenous laser ablation for great saphenous varicose veins. BJS 2018; 105: 686-691.
Authors: S. Vähäaho, K. Halmesmäki, A. Albäck, E. Saarinen, M. Venermo
Notes: More foam recurrences